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                                           INTRODUCTION 
 
                  The oral route is considered as the most promising route of drug delivery. 
Conventional drug delivery system achieves as well as maintains the drug concentration within 
the therapeutically effective range needed for treatment only when taken several times a day. 
This results in a significant fluctuation in drug levels. Recently several advancements have led 
to the development of several novel drug delivery systems (NDDS) that could revolutionize 
method of medication and provide a number of   therapeutic benefits.[1] 
                 The de novo design of an oral controlled drug delivery system (DDS) must be 
primarily aimed to achieving more predictable and increased bioavailability of drugs. 
                However, the development process is precluded by several physiological difficulties, 
such as inability to restrain and localize the DDS within the desired regions of the GIT and the 
highly variable nature of the gastric emptying process. It can be anticipated that, depending 
upon the physiological state of the subject and the design of pharmaceutical formulation, the 
emptying process can last from a few minutes to 12hrs. 
                This variability may lead to unpredictable bioavailability and time to achieve peak 
plasma levels, since the majority of drugs are preferentially absorbed in the upper part of the 
small intestine. Furthermore, due to the relatively brief gastric emptying time (GET) in humans, 
this normally has an  average of 2-3 hrs through the major absorption zone (stomach or upper 
part of the intestine), it can result in incomplete drug release from the (DDS) leading to 
diminished efficacy of the administered dose.  
             Thus control of placement of a DDS in a specific region of the GIT offers numerous 
advantages, especially for drugs exhibiting an absorption window in the (GIT) or drugs with a 
stability problem. These considerations have led to the development of oral controlled – release 
(CR) dosing forms possessing gastric retention capabilities. [2] 
                
            After oral administration, a drug delivery system in such a manner, would be retained in 
the stomach and would  release the drug in a controlled manner, so that the drug could be 
supplied  continuously to its absorption sites in the (GIT). Gastro-retentive drug delivery is an 
approach to prolong to residence time, thereby targeting site-specific drug release in the upper 
gastrointestinal (GIT) for local or systemic effects. 
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BASIC GASTROINTESTINAL TRACT PHYSIOLOGY 
Stomach physiology: 
Anatomically the stomach is divided into 3 regions: fundus , body and antrum(pylorus). The 
proximal part  is made of fundus  and the body acts as a reservoir for undigested material, 
whereas the antrus is the main site for mixing motions and act as a pump for gastric emptying by 
propelling actions. 
 
 
 
 
Fig 1: Physiology of Stomach 
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FUNCTIONS OF STOMACH[3]: 
  Temporary food storage 
 Controls the rate at which food  
 enters the duodenum 
 Acid secretion and antibacterial action 
 Fluidisation of the stomach contents 
 Preliminary digestion with pepsin, lipases etc 
 
Gastric emptying[4]: 
       Gastric emptying occurs during fasting as well as fed states. The pattern of motility is 
however distinct in both the states. During the fasting state an inter digestive series of electrical 
event takes place, which cycle both through the stomach and intestine every 2 to 3 hours. This is 
called  interdigestive myoelectric cycle or migrating myo electric cycle (MMC), which is further 
divided into following 4 phases by Wilson and Washington. 
 
                              Table 1: Phases of  Migrating Myoelectric Cycle (MMC) 
     Phases         Name    Duration      Nature 
Phases 1 Basal phases 45-60min Rare contractions 
Phases 2 Pre-burst phases 30-45min Intermittent peristaltic 
contraction which gradually 
increase in intensity frequency 
Phases 3 Burst phases or “house 
keeper waves” 
5-15min Large intense peristaltic 
contraction. 
Phases 4 Brief transitional phases 0-5 min Occurs between phases 3 and 
phases 1 of the cycle. 
  
  After the ingestion of food, the pattern of contractions changes from fasted to that of fed state. 
This is also known as digestive motility pattern and comprises continuous contraction as in 
phases II of fasted state.  
These contractions result in reducing the size of food particles (to less than 1mm), which are 
propelled toward the pylorus in a suspension form. 
During the fed state, onset of MMC is delayed, resulting in slowdown of gastric emptying rate. 
Scintigraphic studies which are used to determine gastric emptying rates revealed that orally 
administered controlled release dosage forms are subjected that of short gastric residence time 
and unpredictable gastric emptying rate. 
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SUITABLE DRUG CANDIDATES FOR GASTORETENTION[5]: 
1. Drugs that are having  narrow absorption window in GIT( e.g. L-DOPA, P-aminobenzoic 
acid, Furosemide, Riboflavin) 
2. Drugs those are locally active in the stomach(e.g. misroprostol, antacids) 
3. Drugs those are unstable in the intestinal or colonic environment (e.g. Captopril, 
Randitine HCl, and Metronidazole) 
4. Drugs that disturb normal colonic microbes( e.g. antibiotics used for the eradication of 
Helicobacter pylori, such as tetracycline, Clarithromycin, Amoxcillin). 
5. Drugs that exhibit low solubility at high pH values (e.g. diazepam, Chlordiazepoxide, 
Verapamil) 
 
 
 
FACTORS AFFECTING GASTRIC RETENTION[6]: 
 
The gastric retention (GRT) of dosage form is controlled by several factors, which affect 
their efficacy as a gastro retentive system. 
 
 Density- Density of a dosage form affects the gastro retention time of the 
dosage form. 
 
 Size –Dosage forms with a diameter of more than 9.5mm are reported to 
have an increased GRT. 
 
 Shape of dosage form – Tetrahedron and ring-shaped device with a 
flexural modulus of 48 and 22.5 kilo pounds per square inch (KSI) were 
reported to have better GRT i.e 90% to 100% retention at 24 hours 
compared with other shapes. 
 
 Fed or unfed state- Under fasting conditions, the GI motility is 
characterized by periods of strong motor activity or the migrating 
myoelectric cycle (MMC) that occurs every 1.5 to 2 hours. 
The MMC sweeps undigested material from the stomach and if the timing 
of administration of the formulation coincides with that of the MMC, the  
GRT of the unit is expected to be very short. However, in this state, MMC 
is delayed and GRT is considerably longer. 
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 Nature of meal- Feeding of indigestible polymers or fatty acid salts 
will change the motility pattern of the stomach to a fed state, thus 
decreases the gastric emptying rate and helps to prolong drug release. 
 
 Caloric content- GRT can be increased by four to 10 hours with a meal 
that is high in proteins and fats. 
 
 Frequency of feed-  The GRT can increase by over 400 minutes when 
successive meals are given compared to a single meal due to the low 
frequency of MMC. 
 
 Gender- Mean ambulatory GRT in males (3.4±0.6 hours) is less when 
compared to their age and race-matched female counterparts (4.6±1.2 
hours), regardless of the weight, height and body surface. 
 
 Age- Elderly people, especially those over 70, have a significantly 
longer GRT. 
 
 Posture- GRT can vary between supine and upright ambulatory states 
of the patient. 
 
 Concomitant drug administration- Anticholinergic drugs like 
Atropine  and Propantheline 
 
 Biological factors: Diabetes and crohn’s disease. 
 
TYPES OF GASTRORETENTIVE DOSAGE FORMS[6][7] 
1) FLOATING DRUG DELIVERY SYSTEMS 
Floating drug delivery systems (FDDS) have a bulk density less than that of gastric fluids 
and so remain buoyant in the stomach without affecting the gastric emptying rate for a 
prolonged period of time. While the delivery system is floating on the gastric contents, 
the drug is released slowly at a desired rate from the system. After the release of the drug, 
the residual system is emptied from the stomach. This resulted in increased GRT and 
better control of the fluctuations in plasma drug concentration. 
Floating drug delivery systems can be further divided into: 
 
a) Non-effervescent system 
b) Effervescent system 
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2) EXPANDABLE SYSTEMS 
               Expandable gastroretentive dosage forms (GRDFs) have been designed over the past 3 
decades. These GRDFs are easily swallowed and reach a significantly larger size in the stomach 
due to swelling or unfolding processes that improve their GRT. After the drug release, their 
dimensions are minimized with subsequent evacuation from the stomach. 
 
3) BIO/ MUCO-ADHESIVE SYSTEMS 
                   Bio adhesive drug delivery systems (BDDS) are used as a delivery device within the 
lumen to enhance the drug absorption in a site-specific manner. This approach involves the use 
of various bioadhesive polymers, which can adhere to the epithelial surface in the stomach.  
Gastric mucoadhesion  does not tend to be strong enough to impart to the dosage forms, the 
ability to resist the strong propulsion forces of the stomach wall. The continous production of the 
mucous by the gastric mucosa to replace the mucous which is lost through peristaltic 
contractions and the dilution of the stomach content also seem to limit the potential of 
mucoadhesion as a gastroretentive force.  
Some of the most promising excipients that have been used commonly in these systems include 
polycarbophil, carbopol, lecithins etc. 
 
4) HIGH-DENSITY SYSTEMS 
                    Sedimentation has been employed as  retention mechanism for pellets that are small 
enough to be retained in the rugae or folds of the stomach body near the pyloric region, which is 
part of the organ with the lowest position in a upright posture.   
Dense pellets (approximately 3g/cm3) that are trapped in rugae also tend to withstand the 
peristaltic movements of the stomach wall. With the pellets, the GI transit time can be increased 
to an average of 5.8-25 hours, depending more on density than on the diameter of the pellets. 
Commonly used excipients are barium sulphate, zinc oxide, titanium oxide and iron powder, etc. 
These materials increase density by up to 1.5-2.4g/cm-3. 
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Fig 2: Types of GRDDS 
 
FLOATING DRUG DELIVERY SYSTEM[8] 
                     Floating drug delivery systems are also called as hydrodynamically balanced 
systems that float on the gastric contents to release the drug slowly from the dosage form. It is 
further divided into: 
 
a) Non effervescent systems: 
                     This type of system, after swallowing, swells unrestrained via inhibition of gastric 
fluid to an extent that prevents their exit from the stomach. One of the formulation methods of 
such dosage form involved the mixing of the drug with a gel, which swells when in contact with 
the gastric fluid after oral administration and maintains a relative integrity of shape and a bulk 
density less than one within the outer gelatinous layer. The air trapped by the swollen polymer 
offers buoyancy to these dosage forms. 
 Excipients which are most commonly used include hydroxyl propyl methyl cellulose (HPMC),   
polyacrylate polymers, polyvinyl acetate, carbopol, agar, sodium alginate, calcium chloride, 
polyethylene oxide and polycarbonates. 
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This system can be further divided into four sub-types: 
 
(i) Colloidal gel barrier system 
Sheth and Tossounian first designed this ‘hydrodynamically balanced system’. Such a 
system contains drug with gel-forming hydrocolloids meant to remain buoyant on the 
stomach contents. This prolonged the GRT and maximized the amount of drug that 
reached its absorption sites in the solution form for ready absorption. This level 
incorporated a high level of one or more gel-forming highly soluble cellulose type 
hydrocolloid, e.g. hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxyl propyl 
methyl cellulose (HPMC), polysaccharides and matrix-forming polymer such as 
polycarbophil, polyacrylate and polystyrene. On coming in contact with the gastric 
fluid, the hydrochloride in the system hydrated and formed a colloid gel barrier 
around its surface. 
 
ii)  Micro-porous compartment system: 
             This technology is based on the encapsulation of a drug reservoir inside a micro 
porous compartment with pores along its top and bottom walls. The peripheral walls of 
the drug reservoir compartment are  sealed to prevent any direct contact of gastric surface 
with the undissolved drug. In the stomach, the floatation chamber containing the 
entrapped air causes the delivery system to float over the gastric content. Gastric fluid 
enters through the aperture, dissolves the drug and transports the dissolved drug for 
continuous transport across the intestine for absorption. 
 
(iii) Alginate beads: 
         Multi-unit dosage forms are developed from freeze-dried calcium alginate. 
Spherical beads of approximately 2.5 mm in diameter is  prepared by dropping sodium 
alginate solution into aqueous solution of calcium chloride, using the precipitation of 
calcium alginate. The beads are then separated, snaped frozen in liquid nitrogen and 
freeze dried at 400C for 24 hours, leading to the formation of a porous system which can 
maintain a floating force for over 12 hours. These floating beads gave a longer residence 
time of more than 5.5 hours. 
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(iv) Hollow microspheres/ Micro balloons 
                          Hollow microspheres which are loaded with drug in their outer polymer 
shelf are prepared by novel emulsion solvent diffusion method. The ethanol/ 
dichlormethane solution of the drug and enteric acrylic polymer was poured into an 
agitated solution of Poly Vinyl Alcohol (PVA) and was thermally controlled at 400C. The 
gas phase was generated in the dispersed polymer droplet by the evaporation of 
dichloromethane formed and the internal cavity in the microsphere of the polymer with 
drug. The microballoon floated continuously on the surface of an acidic dissolution 
media containing the surfactant for more than 12hrs. 
 
 
b)  Effervescent System 
                            These buoyant systems utilizes matrices prepared with swellable 
polymers such as methocel, polysaccharides (e.g. chitosan), effervescent compound ( e.g. 
sodium bicarbonate, citric acid, tartaric acid). The system is  prepared so that upon arrival 
in the stomach,carbon dioxide is released, causing the system to float in the stomach. 
Other approaches and materials that have been reported are a mixture of sodium alginate 
and sodium bicarbonate, multiple unit floating pills that evolve carbon dioxide when 
ingested, floating minicapsules with a core of sodium bicarbonate, lactose and 
polyvinylpyrolidine are coated with hydroxyl propyl methyl cellulose (HPMC) and 
floating systems based on ion exchange resin technology etc. 
     
 
 
 
                                                 
 
Fig 3: Effervescent system 
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Mechanism of Floating Drug Delivery System[9]: 
 
                                      Floating drug delivery systems (FDDS) have a bulk density lesser 
than gastric fluids, so they remain buoyant in the stomach without affecting the gastric 
emptying rate for a prolonged period of time. While the system is floating on the gastric 
contents, the drug is released slowly at a desired rate from the formulation.  
 
However, a minimal gastric content is needed to allow the proper achievement of the 
buoyancy retention principle, a minimal level of floating force (F) is also required to keep 
the dosage form reliably buoyant on the surface of the meal.  
To measure the floating force kinetics, a novel apparatus for determination of resultant 
weight was reported. The apparatus operates by measuring continuously the force 
equivalent to F(as a function of time) that is required to maintain the submerged object. 
The object floats better if F is on the higher positive side.  
This apparatus helps in optimizing FDDS with respect to the stability and durability of 
floating forces produced in order to prevent the drawbacks of unforeseeable intragastric 
buoyancy capability variations. 
 
                     
 
 
                               F= Fbuoyancy – Fgravity 
                      
                              = (Df –Ds) gv------ (1) 
 
 
Where F= total vertical force, Df = fluid density, Ds= object density, v=volume and g= 
acceleration due to gravity. 
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Fig 4: Mechanism of Floating Systems 
     
The main requirements for floating drug delivery system are: 
1) It must release contents slowly to serve as a reservoir. 
2) It should  maintain specific gravity lower than gastric contents( 1.004-1.01 gm/cm3) 
3) It should form a cohesive gel barrier. 
 
Advantages of floating drug delivery system[10] 
 Improved drug absorption due to increased gastric residence time and more time 
spent by the dosage form at its absorption site. 
 
 Controlled release of drugs. 
 
 Delivery of drugs is localized  in the stomach. 
 
 Minimizes the mucosal irritation due to drugs, by drug releasing slowly at 
controlled rate. 
 
 Treatment of gastrointestinal disorders such as gastro-oesophageal reflex. 
    
 Simple and convenient equipment for manufacture. 
 
 Easy administration and better patient compliance. 
 
 Site specific delivery. 
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Limitations of Floating Drug Delivery Systems: 
 Must be administered with plenty of water. 
 
 Floating systems are not feasible for those drugs which have solubility or stability 
problems in gastric fluids. 
 
 Drugs such as Nifedipine,  is well absorbed along the entire GI tract and undergoes 
significant first- pass metabolism, may not be suitable candidates for FDDS since the 
slow gastric emptying may lead to reduced systemic bioavalibility. There are limitations 
to the applicability of FDDS for drugs that are irritant to gastric mucosa. 
 
 Gastric retention are influenced by many factors such as gastric motility, pH and presence 
of food. These factors are never constant and hence the buoyancy cannot be predicted. 
 
 Drugs that cause irritation and lesion to gastric mucosa are not suitable to be formulated 
as floating drug delivery systems. 
 
 
FORMULATION OF FDDS: 
Excipients Used in FDDS: 
 
1) Polymers:  
The following polymers are used in the preparation of FDDS- HPMC K4 M, 
Calcium alginate, Eudragit S100, Eudragit RL Propylene foam, Eudragit RS, 
ethyl cellulose, PVA, Polycarbonate, Acrylic polymer and carbopol 
 
2) Inert fatty materials (5%-75%) 
Edible, inert fatty material having a specific gravity of less than one is used to 
decrease the hydrophilic property of formulation and hence increase buoyancy. 
E.g. Beeswax, fatty acids, long fatty acids. Gelucires 39/01. 
 
3) Effervescent agents: 
Sodium bicarbonate, citric acid, tartaric acid, Di-SGC (Di- Sodium Glycine 
Carbonate, CG (Citroglycine). 
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4) Release rate accelerants (5%-60%): 
e.g. Lactose, mannitol 
 
5) Release rate retardants (5-60%): 
e.g. Dicalciumphospate, talc, magnesium stearate 
 
6) Buoyancy increasing agents upto 80%: 
 e.g. Ethyl cellulose 
 
7) Low density material: 
   Polypropylene foam powder (Accurel MP 1000) 
 
POTENTIAL DRUG CANDIDATES FOR FLOATING DRUG DELIVERY SYSTEMS[11]: 
1) Drugs which are locally active in the stomach: e.g.misoprostol, antacids etc. 
 
2) Drugs that have a narrow absorption window in gastrointestinal tract (GIT): e.g. L-
Dopa, Para amino benzoic acid, furosemide, riboflavin etc. 
 
 
3) Drugs that are unstable in the intestinal or colonic environment : e.g. captopril, 
ranitidine, metronidazole. 
 
4) Drugs that disturb the normal colonic microbes: e.g. antibiotics against Helicobacter 
pylori. 
 
5) Drugs those exhibit low solubility at high pH values: e.g. diazepam, chlodiazepoxide, 
verapamil HCl. 
 
APPLICATIONS OF FLOATING DRUG DELIVERY SYSTEMS[12]: 
 
1) Enhanced bioavailability: 
   The bioavailability of riboflavin CR-GRDF was significantly enhanced in 
comparison to the administration of non-GRDFCR polymeric formulations. There are 
several processes, related to the absorption and transit of the drugs in the 
gastrointestinal tract, that act commitantly to influence the magnitude of drug 
absorption. 
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2) Sustained Drug delivery: 
    Oral CR formulations were encountered with problems such as gastric residence 
time in the GIT. These problems can be overcomed with HBS systems which can 
remain in the stomach for long periods and have a bulk density< 1 as a result of 
which they can float on the gastric contents. These systems are relatively larger in 
size and passing from the pyloric opening is barred. 
 
3)  Site specific drug delivery systems: 
      These systems were particularly advantageous for drugs that are specifically 
absorbed from the stomach or proximal part of the small intestine. The controlled, 
slow delivery of the drug to the stomach provides sufficient local therapeutic level 
and limits the systemic exposure to the drug. This reduced the side effects that are 
caused by the drug in the blood circulation. In addition, the increased gastric 
availability from a site directed delivery system may also reduce the dosing 
frequency. Eg. Furosemide and Riboflavin. 
 
4) Absorption enhancement 
     Drugs that are having poor bioavalibility because of site specific absorption from 
the upper part of the GIT are potential candidates to be formulated as floating drug 
delivery systems, thereby maximizing their absorption. 
 
5) Minimized adverse activity at the colon: 
           Retention of the drug in the HBS systems at the stomach minimized the 
amount of drug that reaches the colon. Thus, undesirable activities of the drug in 
colon was prevented.   
 
GRDF formulation for betalactum antibiotics  were absorbed from the small intestine, 
and its presence in the colon led to the development of micro organism’s resistance. 
 
6) Reduced fluctuations of drug concentration: 
   Continuous input of the drug following CRGRDF administration produced blood 
drug concentrations within a narrower ranges compared to the immediate release 
dosage forms. Thus, fluctuations in drug effects are reduced and concentration 
dependent adverse effects that are associated with peak concentration. 
Literature Review
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LITERATURE REVIEW
Kristl et al.
[13]
investigated the development of floating matrix tablets, which after oral 
administration were designed to prolong the gastric residence time, increase the drug 
bioavailability and diminish the side effects of the irritating drugs. The importance of the 
composition optimization, the technological process development for the preparation of the 
floating tablets with a high dose of freely soluble drug and characterization of those 
tablets(crushing force, floating properties in vitro and in vivo, drug release) was examined. 
Tablets containing hydroxypropyl methyl cellulose (HPMC), drug and different additives were 
compressed. The investigation shows that tablet composition and mechanical strength have the greatest 
influence on the floating properties and drug release. With the incorporation of a gas-generating agent 
together with microcrystalline cellulose, besides optimum floating(floating lag time, 30s; duration of 
floating, >8 hrs), the drug content was also increased. The drug release from those tablets was sufficiently 
sustained (more than 8hrs) and non-Fickian transport of the drug from tablets was confirmed. 
Radiological evidence suggests that, the formulated tablets did not  adhere to the stomach mucus and that 
the mean gastric residence time was prolonged(>4hrs).
Srividya et al
[14]
. developed gastro retentive floating matrix tablets of Quetiapine fumarate by 
using various hydrophilic polymers. The formulation was developed by using different 
concentrations of polymers of various grades of HPMC and guar gum. The gas generating agent 
of sodium bicarbonate was optimized. The formulation blend was subjected to various 
preformulation studies, and all the formulationswere found to be indicating that the powder blend 
has good flow properties. Among all the formulations, the formulations prepared by guar gum 
were unable to produce desired drug release; they were unable to retard drug release upto 
12hours. The formulations prepared with HPMC K15 M retarded the drug release upto 12hours 
in the concentration of 120 mg (F6). The formulations prepared with HPMC K100 M (F8) also 
retarded the drug release for more than 12 hours. Hence they were not considered. The optimized 
formulation dissolution data was subjected to release kinetics; from the release kinetics data it 
was evident that the formulation followed Higuchi mechanism of drug release.
Bhandari et al
[15]
. developed chronomodulated floating drug delivery system for famotidine; the 
formulations were evaluated and optimized for their desired effect. By using present drug 
delivery system, famotidine was delivered locally to the stomach with a certain period of lag 
time. Different levels of percentage weight ratio of ethyl cellulose to hydroxypropyl cellulose 
and different coating levels were successfully optimized by using statistical analysis. Combing 
32 factorial design and response surface methodology % weight ratio of polymers and coating 
levels were optimized for desired lag time of off release and cumulative drug release. Response 
surface methodology represents combined effect of both independent variables on dependent 
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variables. So we can predict optimum levels of independent variables for desired responses. For 
the present study of formulating chronomodulated drug delivery system optimized coating level 
percentage weight gain was 7.50% and the percentage weight ratio of ethyl cellulose to 
hydroxypropyl methyl cellulose was 78.50% that gave observed lag time of 218 minutes and 
percentage cumulative drug release of 88.21% with minimum percentage error with predicted 
values from the software.
Ying-Chen Chen et al
[16]
. developed effervescent multiple-unit floating drug delivery systems 
to prolong the gastric residence time and to improve the overall bioavailability. These systems 
comprised of the drug (losartan), effervescent agent (sodium bicarbonate) containing pellets 
coated with a blended polymeric membrane which was a mixture of gastro intestinal soluble and 
insoluble polymers. The addition of GIT- soluble polymers such as HPMC,  PEG 6000 increased 
the water uptake ability of the GIT-insoluble polymers and helped to initiate the effervescent 
reaction and float, but the hydrated films was impermeable to the generated CO2 and thereby 
helped to maintain the floatation. It was sufficiently flexible to withstand the pressure of carbon 
dioxide to avoid rupturing. The study demonstrated that the water uptake ability and mechanical 
properties can be applied as screening tools during the development of effervescent muFDDSs. 
The optimized system of SRT(5) P600(5) (i.e a mixture of 5% Kollicoat SR and 5% PEG 600) 
with a 20% coating level started to float within 15minutes and maintained its buoyancy over a 
period of 12hrs with sustained release effect.
Rajani Shakya et al
[17]
. developed hydrophilic matrix based controlled release gastro retentive 
drug delivery system of ofloxacin and its in-vitro and in-vivo evaluations. Effervescent floating 
gastro retentive drug delivery system of ofloxacin was prepared by utilizing Box-Behnken 
statistical designs. Formulation was optimized by setting targets on selected responses. In- vivo 
were carried out for the optimized formulation with 12 healthy volunteers and the obtained 
pharmacokinetic parameters were compared with the marketed daily once formulation.
Optimized formulation showed satisfactory controlled in-vitro drug release for more than 12hrs, 
having excellent buoyancy properties(floating lag time<1min, floating duration > 16hrs). The 
optimized and marketed formulations were found to have similar in-vitro release profile 
(f2=79.22) and were also found to be bioequivalent. Cmax and AUC  values of optimized 
formulation were found to be significantly higher than that of marketed formulation despite their 
bioequivalence.
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Govikari Koteshwar Rao et al
[18]
designed and developed gastro retentive dosage forms for 
cefuroxime axetil using floating tablet approach with various grade of hydroxyl propyl methyl 
cellulose. Sodium bicarbonate was used in the dosage form as a source of effervescent agent to 
maintain buoyancy. In vitro dissolution study results indicated that the formulation was non-
Fickian diffusion controlled release mechanism and it was best fitted into Korsmeyer-Peppas 
equation. In vivo radiographic studies was conducted in five healthy human volunteers for the 
optimized formulation and it indicated over 6hr retention of tablet in the stomach region. 
Friederike Eisenacher et al
[19]
evaluated the performance of Co2 generating floating bi layer 
tablets with respect to robustness, drug release profile, pH dependence and floating behaivour. 
Bilayer tablets were coated with a flexible and water permeable, but CO2- retaining polymer film 
of polyvinyl acetate or ammonio-methacrylate copolymer type A. Metformin HCl was used as a 
relevant model drug due to its dose dependency and saturable absorption from the proximal part 
of the small intestine. To mimic the physiological relevant mechanical stress conditions, 
dissolution stress tests were recently developed and pulsed pressures were applied in addition to 
release studies according to the pharmacopoeia. Bilayer tablets coated with polyvinyl acetate 
showed short floating lag time, floating duration of more than 24 hrs in simulated gastric fluid 
and a robust and pH independent release of Metformin HCl. Tablets that are coated with 
ammonio- methacrylate copolymer type A showed higher permeability for the active ingredient 
combined with a decreased robustness of the inflated tablets. Both polymers are used for balloon 
like floating devices. The appropriate polymer chosen is dependent on the properties of active 
ingredient and the application of the delivery device was requested. 
Chandrasekhara Rao Baru et al
[20]
developed ibuprofen floating tablets by using various 
polymers such as HPMC K4M and Carbopol 940 to enhance the bioavailability and therapeutic 
efficacy of ibuprofen. The floating tablets of ibuprofen are prepared by direct compression 
method. Four formulations (F1 to F4) were prepared by using variable concentrations of HPMC 
K4 and Carbopol 940. DSC analysis was performed to ensure there were no interactions between 
drug and the polymers. The optimized formulation showed satisfactory release for more than 12 
hours, have shorter floating lag time increased bioavailability. 
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Navjot Singh et al
[21]
developed a gastro retentive system for tizanidine hydrochloride. Floating 
matrix tablets of tizanidine hydrochloride were prepared by employing hydroxyl propyl methyl 
cellulose as encapsulant using wet granulation technique. The precompression parameters for the 
floating tablets were evaluated. The drug and polymer interaction was evaluated by Fourier 
transform infra red spectroscopy. The gastroretentive activity of the floating tablets of THC was 
evaluated in vitro as well as in vivo using gamma scintigraphy technique in healthy human 
volunteers. The effect of polymer concentration, polymer viscosity on drug release profile was 
investigated. It was observed that the concentration of HPMC plays an important role in 
controlling the in vitro drug release profile of the formulations. The increase in HPMC retards 
the release of drug from the formulation. The in vivo study by gamma scintigraphic in the human 
volunteers by Tc 99M has shown that the floating tablet of  THC can maintain its integrity under 
harsh conditions in the human stomach.
Mudgal Vinod Kumar et al
[22]
developed a sustained  release floating system using 
ciprofloxacin as a model drug that was able to float for an extended period of time. The system 
consisted of a 3mm drug containing gas generating core which is formulated by direct 
compression and coated with a flexible polymeric membrane. Eudragit RL30D and ATEC were 
used as a film former and plasticizer respectively. As the proportion of effervescent agents 
increased, the floating time decreased. The optimized coated floating tablets floated within 
20min and remained buoyant for more than 13hrs. A sustained release of ciprofloxacin for more 
than 13 hrs was observed. The time of floatation can be controlled by the composition (type of 
filler, concentration of effervescent agents) and the hardness of the tablet core and the 
composition (type of polymer and plasticizer) and thickness of the coating.
Ligam Meka et al
[23]
developed a gastro retentive floating drug delivery system with multiple-
unit minitab’s based on gas formation technique in order to prolong the gastric residence time 
and to increase the overall bioavailability of the drug. The system consisted of the drug-
containing core units prepared by direct compression process, which were coated with three 
successive layers of an inner seal coat, effervescent layer (sodium bicarbonate) and an outer gas-
entrapped polymeric membrane of a polymethacrylates (Eudragit RL30D, RS30D,  and 
combinations of them. The system which used Eudragit RL 30D and combination of them as a 
gas-entrapped polymeric membrane could float. The optimized formulation floated completely 
within 3min and maintained the buoyancy over a period of 12 hrs. The drug release was 
controlled and linear with the square root of time. As the coating level of gas-entrapped
polymeric membrane was increased, the drug release was decreased. Both rapid floating and the 
controlled release properties were achieved in the multiple-unit floating drug delivery system 
which was developed in the present study. The analysis of the parameter dissolution data after 
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storage at 40
0
C and 75% RH for 3 months showed no significant change hence indicating the 
two dissolution profiles to be similar (f2 value is more than 50).
Suraj Aghav et al
[24]
developed floating gastro retentive system of simvastatin to increase the 
gastric retention time and the bioavailability. From the findings of various physical, chemical 
and in-vitro tests, it is concluded that initially the drug was confirmed by characterization by UV 
spectroscopy, FT-IR spectroscopy and Differential Scanning Calorimetry. Sodium bicarbonate 
15% (30mg) and citric acid 5% (10mg) imperative to achieve in vitro buoyancy. From the 
preliminary trial batches containing individual polymer, it was confirmed that 35% (70mg for 
200mg tablet) of Polyvox WSR 205 and Polyvox WSR N12K was required to achieve in vitro
buoyancy as well as desired drug release pattern. After the dissolution profile of preliminary trial 
batches, it was concluded that as polymer concentration increases, drug release decreases. 
Formulations were prepared as per 3
2
full factorial design.
Garje Pravin et al
[25]
formulated a gastro retentive drug delivery system of Metoprolol tartrate. 
Sodium bicarbonate and citric acid were used as the effervescent agent. The effects of citric acid 
and sodium bicarbonate on drug release profile and floating properties were evaluated. 3
2
full 
factorial design was applied to systemically optimize the drug release profile. The amounts of 
HPMC K 15M (X1) & HPMC  K100M (X2) were selected as  independent variables & lag time 
(Y1), float time (Y2), percent drug release (Y3) were selected as dependent variables. According 
to the full factorial design , combination of HPMC K15M and HPMC K100M polymer favours 
the sustained release of metoprolol tartrate  from a gastro retentive formulation. Batch F5 
showed the highest drug release, (97.11%) have floating lag time of 49sec and floating time of 
12hrs.
Aleksandar Aleksovski et al
[26] 
developed controlled release effervescent matrix tablets which 
was meant to float over the gastric media for more than 8hrs and the active compound was 
released in a continous manner. Ranitidine HCl was used as a model drug which has narrow 
absorption window in the small intestine. Sodium bicarbonate and citric acid was employed as 
effervescent compounds and two different types of hydroxyl propyl methyl cellulose (HPMC K4 
and HPMC K15M) were used as controlled release hydrophilic polymers.
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Three batches of tablets were formulated (one containing HPMC K4, other having HPMC K15M 
and the third containing 1:1 mixture of these polymers). Every batch was compressed with two 
different forces 5.5kN and 4.7kN, hence completely six probes of tablets were made. All six 
probes complied to the pharmacopoeial requirements containing mass uniformity, friability and 
hardness.all the six probes floated fast to the surface of the medium and tended to hydrate and 
swell fast enough whose actions provided controlled release of the compound forover a period of 
8hours. No significant differences were noticed in the dissolution profiles of all six probes during 
investigation.
M.A. Hassan et al
[27]
developed a gastro retentive drug delivery system for water-soluble H2 –
receptor antagonist drug namely ranitidine hydrochloride. The floating and controlled-release 
properties of tablets containing ranitidine HCl, HPMC and other additives were evaluated. The 
study showed that tablet composition and mechanical strength have the greatest influence on 
floating properties and drug release. Sodium bicarbonate was used as the gas generating agent. 
The time taken for the tablets to emerge on the water surface (floating lag time) or buoyant time, 
and the time during which the tablets constantly float on the water surface were evaluated. The 
results indicated that the buoyancy was strong enough for the whole tablets to travel up to the 
surface and remain on the surface as long as 24hrs. Drug release from the drug was sufficiently 
sustained and the drug release fit  both Higuchi and Peppas model. The floating tablets were 
compared  with conventional tablets in fasted rabbits at 150mg equivalent dose of ranitidine HCl. 
The pharmacokinetic parameters were calculated.
Dave et al
[28]
prepared a gastroretentive drug delivery system of ranitidine hydrochloride. Guar 
gum, xanthum gum and hydroxyproyl methyl cellulose were evaluated for gel-forming 
properties. Sodium bicarbonate was incorporated as gas generating agent. The effects of citric 
acid and stearic acid on drug release profile and floating properties were investigated. The 
addition of stearic acid reduces the drug dissolution due to its hydrophobic nature. A 32 full 
factorial design was applied to systemically optimize the drug release profile. The amounts of 
citric acid anhydrous (XI) and stearic acid (X2) were selected as independent variables. The 
times required for 50% (t50) and 80% drug dissolution (t80), and the similarity factor f2 were 
selected as dependent variables. The results of the full factorial design indicated that a low 
amount of citric acid and a high amount of stearic acid favours sustained release of ranitidine 
hydrochloride from a gastroretentive formulation. A theoretical dissolution profile was generated 
using pharmacokinetic parameters of ranitidine hydrochloride.
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Ali Kadavar et al
[29]
developed floating sustained-release Imatinib tablets to overcome the 
inadequacy of conventional tablets. Tablets were formulated using HPMC K4, Sodium Alginate 
and Carbomer 934P as release retarding polymers, sodium bicarbonate as the effervescent agent 
and lactose as a filler. Floating behaivour, in vitro drug release, and the swelling index studies 
were conducted. The initial and final drug release duration was compared with a commercial 
tablet. Tablets were evaluated for various physical parameters including weight variation, 
thickness, hardness, friability and drug content. Consequently, 6 months of physical stability 
studies and in vitro gastro-retentive studies were conducted.
Pramod patel et al
[30]
The present study concerns the development of floating tablets of 
ofloxacin which were designed to prolong the gastric residence time after oral administration. 
Ofloxacin is a fluoroquinolone antibacterial agent which is highly effective against gram positive 
and gram negative bacteria. Ofloxacin floating tablets were prepared by wet granulation method 
incorporating natural polymer like guar gum, locust bean gum, either alone or in combination 
with HPMC K100 M as swelling polymers with sodium bicarbonate as gas generating agent and 
were evaluated for parameters such as weight variation, hardness, friability, drug content, 
swelling index, in vitro buoyancy study and in vitro drug release studies. All the formulation 
showed compliance with pharmacopeia standards. Based on the evaluation results, F3 and F6 
formulations were selected as the best formulation was well controlled and uniform throughout 
the dissolution studies. The drug release of optimized formulation follows the Higuchi kinetic 
model, and the mechanism is found to be non-Fickian / anomalous according to Korsmeyer-
Peppas equation.
Thakur et al 
[31]
developed floating matrix tablets of clarithromycin to prolong the gastric 
residence time after oral administration, at a particular site and controlling the release of drug 
especially useful for achieving controlled plasma level as well as for improving bioavailability. 
The tablets were compressed using wet granulation technique. The optimized formulation gave 
floating lag time less than 30 seconds and had a total floating time more than 10hours.
Prasad garrepally et. al
[33]
developed an intragastric drug delivery system of propanolol 
hydrochloride, and investigated the ability of  various natural polymers to retain the drug when 
used in different concentrations. Mango resin i.e. Mangifera indica was evaluated for their gel 
forming abilities. Prepared formulations were evaluated for pre-compression properties like flow 
of granules, bulk and tapped density, post-compression properties like uniformity of weight, 
hardness, friability, thickness, in-vitro buoyancy characteristics, drug contenting-vitro drug 
release profile and mechanism of drug release. All the prepared batches showed good in-vitro
buoyancy. It was also found that in-vitro drug release on increasing the amount of natural
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retardant polymer mango resin. The kinetic of drug release from all the formulations followed 
the zero by regression analysis and further mechanism of drug release was confirmed by 
Higuchi’s and Korsemeyer’s model showed that non-fickian and anomalous drug release. Finally 
optimized formulation was compared with marketed SR tablet which showed similarity factor 
value 75.35.
                                                                                  Aim and Objective
                                             AIM AND OBJECTIVE
• To design, formulate & evaluate floating matrix tablets containing Ezetimibe based on 
effervescent technology in order to increase gastric retention time.
• To evaluate  the influence of preparative parameter and its  effect  on drug release and 
floating ability of the formulation.
• To evaluate the in-vitro release profile of Ezetimibe and evaluate the release mechanism 
on the basis of various kinetic models.
• To  evaluate  the  stability  studies  for  samples  which  analysed  for  drug  content, 
characteristics and in-vitro dissolution studies.
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PLAN OF WORK
1. Literature review
2. Pre-formulation studies
3. Preparation of tablets by direct compression method
4. Evaluation of tablets for:
a. Hardness
b. Thickness
c. Friability
d. Weight variation
e. Content uniformity
f. Assay
g. Floating lag time
h. Floating duration
i. Matrix integrity
j. Dissolution studies
5. Kinetic model analysis
a. First order
b. Zero order
c. Higuchi model
d. Korsmeyer-peppas model
6. Stability studies  
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DRUG PROFILE
Ezetimibe[33][34]
Chemical IUPAC                               : (3R, 4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-
                                                            -3- hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
Empirical Formula                             : C24H21F2NO3
Structural Formula                             :
Molecular weight                               :  409.4 g/mol
Description                                         : white fine powder
Storage                                              :  Store at 25⁰C (59-86 F)
Melting point                                     : 164 to 166⁰C   
Solubility                                           :  Insoluble in water and soluble in methanol
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Mechanism of Action:
Ezetimibe  inhibits  the  absorption  of  cholesterol  from  the  small  intestine  and  decreases  the 
amount  of  cholesterol  normally  available  to  liver  cells,  leading  them to  absorb  more  from 
circulation and thus lowering levels  of circulating cholesterol.
Dosing:
 10mg once daily
PHARMACOLOGY:
Pharmacodynamics:
Eztimibe  is  a  drug  that  lowers  plasma  cholesterol  levels.  It  acts  by  decreasing  cholesterol 
absorption in the small intestine. Ezetimibe is recommended as second line therapy for those 
intolerant of statins or unable to achieve the target LDL cholesterol levels by statins  alone.
Ezetimibe is indicated in the United States as an add-on to dietary measures to:
• Reduce levels of certain lipids in people with primary hyperlipidemia, alone or with a 
statin;
• Reduce levels of certain lipids in people with primary hyperlipidemia alone or with a 
statin;
• Reduce levels of certain lipids in people with mixed hyperlipidemia, in combination with 
fenofibrate;
• Reduce levels of certain lipids in people with homozygous familial hypercholesterolemia, 
in combination with specific statins;
• Reduce levels of certain lipids in people with homozygous sitosterolemia.
Pharmacokinetics:
Absorption:
Within 4-12 hours of the oral administration of a  10mg dose to fasting adults, the attained mean 
ezetimibe peak plasma concentration (Cmax) was 3.4-5.5 mg/ml. Following oral administration, 
ezetimibe is absorbed and extensively conjugated to a phenolic glucuronide (active metabolite).).
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Metabolism
Ezetimibe  is  primarily  metabolized  in  the  liver  and  the  small  intestine  via  glucuronide 
conjugation with subsequent renal and biliary excretion.
Distribution
Mean C(max) (45-71 mg/ml) of ezetimibe- glucoronide is attained within 1-2hrs. Ezetimibe and its 
active metabolites are highly bound to human plasma proteins (90%). The bioavailability of the 
drug is 35-65%.
Excretion
Ezetimibe is excreted 11% in renal and 78% in fecal matter. Both the parent compound and its 
active metabolite are eliminated from plasma with a half-life around 22 hours, allowing for once-
daily dosing.
INDICATIONS AND USAGE:
•  Indicated in the treatment of hypercholesterolemia 
Contraindications:
• Previous allergic reaction including rash, angioedema and anaphylaxis and severe liver 
diseases when taken with a statin.
• Ezetimibe  may  have  significant  medication  interactions  with  cyclosporine  and  with 
fibrates other than fenofibrate.
ADVERSE EFFECTS:
Common adverse effects  associated with ezetimibe include headache or  diarhoea.  Infrequent 
adverse effects (0.1-1% of patients) include: myalgia or raised liver function test (AST/ALT) 
results. Rarely(<0.1 % of patients), hypersensitivity reactions (rash, angioedema) or myopathy 
may occur. 
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                                                     POLYMER PROFILE
                                                              HPMC[35]
Nonproprietary Names:
• JP: Hydroxypropylmethylcellulose
• BP: Hypromellose
• PhEur: Hypromellose
Synonyms:
                Benecel MHPC;  E464; hyrodxypropyl methylcellulose; HPMC; Methocel;
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; Tylopur
Chemical name  and CAS Registry Number:
                    Cellulose hydroxypropyl methyl ether[9004-65-3]
Empirical formula and Molecular weight:
             The  PhEur  2005  describes  hypromellose  as  a  partly  O-methylated  and  O-(2-
hydroxypropylated) cellulose. It is available in a several grades that vary in viscosity and extent 
of substitution. Grades may be distinguished by appending a number indicative of the apparent 
viscosity, in mPa s, of a 2% w/w aqueous solution at 200c. Hypromellose defined in the USP 28 
specifies the substitution type by appending a four-digit number to the nonproprietary name: eg; 
hypromellose  1828.  The  first  two  digits  refer  to  the  approximate  percentage  content  of  the 
methoxy group (OCH3). The second two digits refer to approximate percentage content of the 
hydorxypropoxy group (OCH2CH(OH)CH3), calculated on a dried basis. It contains methoxy and 
Hydroxypropoxy group.
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Structural formula:
Functional category:
              Coating agent; film-former; rate-controlling polymer for sustained release; stabilizing 
agent; suspending agent; tablet binder; viscosity-increasing agent.
Applications in Pharmaceutical Formulation or Technology
               Hypromellose is  widely used in  oral,  ophthalmic and topical  pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in film-coating, 
and as a matrix for use in extended-release tablet formulations.  Concentrations between 2% and 
5% w/w may be used as a binder in either wet- or dry-granulation processes. High-viscosity 
grades may be used to retard the release of drugs from a matrix at levels of 10-80% w/w in 
tablets and capsules. Depending upon the viscosity grade, concentrations of 2-20% w/w  are used 
for film-forming solutions to film-coat tablets. Lower-viscosity grades are used in aqueous film-
coating solutions, while higher-viscosity grades are used with organic solvents. Examples of the 
film  coating  materials  that  are  commercially  available  include  AnyCoat  C,  Spectracel,  and 
Pharm  coat. Hypromellose  is  also  used  as  a  suspending  and  thickening  agent  in  topical 
formulations.  Compared  with  methylcellulose,  hypromellose  produces  aqueous  solutions  of 
greater clarity, with fewer undispersed fibers present, and is  therefore preferred in formulations 
for ophthalmic use. Hypromellose at concentrations between 0.45-1.0%w/w may be added as a 
thickening agent to vehicles for eye drops and artificial tear solutions. Hypromellose is also used 
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as  an emulsifier,  suspending agent  and stabilizing agent  in  topical  gels  and ointments.  As a 
protective colloid, it can prevent droplets and particles from coalescing or agglomerating, thus 
inhibiting the formations of sediments. In addition, hypromellose is used in the manufacture of 
capsules, as an adhesive in plastic bandages, and as a wetting agent for hard contact lenses.
Description:
               Hypromellose is an odourless and tasteless, white or creamy-white fibrous or granular 
powder.
Typical properties:
       Acidity/alkalinity: pH=5.5-8.0 for a 1% w/w aqueous solution
       Auto ignition temperature: 3600C
       Density (bulk): 0.341 g/cm3
       Density (tapped): 0.557 g/cm3
       Density (true): 1.326g/cm3
       Melting point: Browns at 190-2000C; chars at 225-2300C. Glass transition temperature is   
       170-1800C.
       Moisture content: Hypromellose absorbs moisture from the atmosphere; the amount of  
       water absorbed depends upon the initial moisture content and the temperature and relative    
       humidity of the surrounding  air.
       Solubility: Soluble in cold water, forming a viscous colloidal solution; practically insoluble 
       in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and 
       dichloromethane, mixtures of methanol and dichloromethane, and mixtures of water and
       alcohol. Certain grades of hypromellose are soluble in aqueous acetone solutions, mixtures
       of dichloromethane and propan-2-ol, and other organic solvents.
       Specific gravity: 126
       Viscosity (dynamic): A wide range of viscosity types are commercially available. Aqueous 
       solutions are most commonly prepared, although hypromellose may also be dissolved in 
       such as ethanol and propan-2-ol provided the alcohol content is less than 50%w/w. 
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       Dichloromethane and ethanol mixtures may also be used to prepare viscous hypromellose
   solutions.  Solutions  prepared  using  organic  solvents  tend  to  be  more  viscous,  
increasing concentration also produces more viscous solutions.
  Table 4: Typical viscosity for 2%(w/v) aqueous solutions of  Methocel (Dow Chemical Co)
Viscosities measured at 200C
           Methocel product   USP 28 Designation  Nominal viscosity(mPa s)
Methocel K15M Premium            2208                 4000
Methocel K50M Premium            2208                 15000
Methocel K100M Premium            2208                 100000
To prepare an aqueous solution, it is recommended that hypromellose is dispersed and 
thoroughly hydrated in about 20-30% of the required amount of water.  The water should be 
vigorously stirred and heated to 80-900C, then the remaining hypromellose should be added. 
Sufficient  cold water  should then be added to  produce the required volume.  When a water-
miscible  organic  solvent  such  as  ethanol  (95%),  glycol,  or  mixtures  of  ethanol  and 
dichloromethane are used, the hypromellose should first be dispersed into the organic solvent, at 
a ratio of 5-8 parts of solvent to 1 part of hypromellose. Cold water is then added to produce the 
required volume.
Stability and Storage Conditions:
          Hypromellose powder is  a stable material,  although it  is hygroscopic after  drying. 
Solutions  are  stable  at  pH  3-11.  Increasing  temperature  reduces  the  viscosity  of  solutions. 
Hypromellose  undergoes  a  reversible  sol-gel  transformation  upon  heating  and  cooling, 
respectively.  The  gel  point  is  50-900C,  depending  upon  the  grade  and  concentration  of  the 
material.
Incompatibilites:
          Hypromellose  is  incompatible  with  some oxidizing  agents.  Since  it  is  nonionic, 
hypromellose  will  not  complex  with  metallic  salts  or  ionic  organics  to  form  insoluble 
precipitates.
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MATERIALS AND METHODS
Table-3: Instruments used
INSTRUMENTS MANUFACTURERS
Single pan analytical balance Shimadzu corporation- Japan
FT/IR Spectroscopy/4100 Jasco, Johannesburg, South Africa
Tablet compression machine (Rimek-MINI PRESS-II MT)
Karnavati engineering Ltd-Gujarat
Hydraulic/pellet press Kimaya engineer, Thane, India
Pfizer hardness tester Shreeji scientific &laboratory 
instruments-Mumbai
Roche Friabilator (Thermonik C-FTA20), 
Campbell electronics- Mumbai
Tap Density Apparatus (Thermonik) Campbell electronics-mumbai
Vernier Calliper Electro lab-mumbai
Dissolution Apparatus Tab Machines, Mumbai, India
UV spectrophotometer Shimadzu, Shimadzu Corporation, Philippines
 Stability Chamber Technico Chennai, India
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MATERIALS SUPPLIERS/MANUFACTURER
Ezetimibe Bafna Pharmaceuticals Ltd-Chennai
HPMC K4 (Methocel)  Colorcon Asia Pvt Ltd
HPMC K15(Methocel)  Colorcon Asia Pvt Ltd
HPMC K100(Methocel)  Colorcon Asia Pvt Ltd
Pregelatinized Starch Colorcon Asia Pvt Ltd
Sodium bicarbonate SD fine chemicals-Mumbai
Cross povidone XL 10 Bafna Pharmaceuticals Ltd, Chennai
Magnesium Stearate Loba Chemie-Mumbai
METHODOLOGY:
PRELIMINARY STUDIES
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Preparation of standard stock solution[36]:
The standard stock solution was prepared by dissolving 10mg of the drug in 5ml of methanol to 
get  a  concentration  of  1000mcg/litre.  It  was  appropriately  diluted  with  methanol  to  get  a 
concentration of 100mcg/litre and was kept as stock solution.
Determination of λmax:
The standard solution of Ezetimibe was scanned in  the UV spectrophotometer  to  obtain the 
maximum wavelength  of  absorption  against  blank  between  wavelengths  of  200-400nm.  The 
standard solution was scanned for absorbance maxima against blank. The maximum absorbance 
was found to be 233nm.
Preparation of calibration curve:
The  stock  solution  of  ezetimibe  was  accordingly  diluted  to  obtain  concentration  range  of  
0-10μg/ml. The absorbance was observed against methanol as blank and the calibration curve 
was plotted between concentration (x-axis) and absorbance (y-axis).
FORMULATION OF FLOATING MATRIX TABLETS:
POLYMER SELECTION[38]:
Trial  batches  of  ezetimibe  floating  matrix’s  tablets  were  prepared  using  different  polymers 
(HPMC K4, HPMC K15, HPMC K100, sodium bicarbonate, PG Starch); drug polymer ratio of 
(1:1) was used. Tablets prepared by direct compression technique and evaluated for floating lag 
time and matrix integrity in HCl and 2% Sodium lauryl sulphate medium.
FORMULATION DESIGN
Floating matrix tablets of Ezetimibe were formulated based on effervescent technique using
• Matrix forming swellable polymer: HPMC K4, HPMC K15, HPMC K100
• Effervescent compounds: Sodium Bicarbonate
• Filler: Pregelatinized Starch
Tablets were prepared by direct compression method. A total of 6 formulations were designed by 
varying the amounts of polymer and sodium bicarbonate.
                             Table 5: Formulation table of floating Tablets of Ezetimibe    
Ingredients F1(mg) F2(mg) F3(mg) F4(mg) F5(mg)  F6(mg)
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Ezetimibe 10 10 10 10 10 10
Cross 
povidone
2 2 2 2 2 2
PG Starch 19.45 19.45 19.45 13.45 13.45 13.45
HPMC K4 25 30 - - - -
HPMC K15 - - 25 30 - -
HPMC K100 - - - - 25 30
Sodium 
bicarbonate
2 2 2 3 3 3
Sodium Lauryl 
Sulphate
1.2 1.2 1.2 1.2 1.2 1.2
Magnesium 
Stearate
0.35 0.35 0.35 0.35 0.35 0.35
PREFORMULATION STUDIES[38][39]
The  discovery  and  development  of   new  chemical  entities(NCEs)  into  stable,  bioavailable, 
marketable  drug  products  is  a  long  but  rewarding  process.  Once  a  NCE  is  selected  for 
development, choosing the molecular form that will be an active pharmaceutical ingredient (API) 
is a critical milestone because all subsequent development will be affected by this decision. A 
well-  designed  preformulation  study is  necessary  to  fully  characterize  molecules  during  the 
discovery and the development process. The procedure of each preformulation tests suitable for 
tablets is given below:
DRUG-EXCIPIENT COMPATIBILITY STUDY BY FTIR
IR spectra matching approach was used for determination of any possible chemical interaction 
between drug and polymers. A physical mixture (1:1) of drug and polymer was prepared and 
mixed  with  suitable  quantity  of  potassium  bromide.  About  100mg  of  this  mixture  was 
compressed to form transparent pellets using a hydraulic press at 6 tons pressure. It was then 
scanned from 4000 to 400 cm-1 in FTIR spectrometer. The IR spectrum of the physical mixture 
was  compared  with  those  of  pure  drug  and  polymers;  matching  was  done  to  detect  any 
appearance or disappearance of peaks.
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PREPARATION OF POWDER BLEND:
            The ingredients were accurately weighed and shifted to sieve #60, and then the materials 
except  talc  and magnesium stearate  were blended using mortar  and pestle  for  10 min in  an 
ascending order. Powder mixture then blended with talc and magnesium stearate for 5 minutes.
EVALUATION OF POWDER BLEND:
Prior to the compression, the formulation powder blends were evaluated for their bulk 
and  tapped  density  and  from  these  values  compressibility  index  and  Hausner  ratio  were 
calculated.  While  the flow properties  of  the  powder  blend were accessed from the  angle  of 
repose.
1. Bulk density and tapped density[40]:
       Both  loose  bulk  density(LBD)  and  tapped  bulk  density(TBD)  were  determined. 
Accurately weighed amount of granules were taken in a 25ml measuring cylinder of Borosil and 
measured/recorded for the volume of packing, then tapped 100 times  on a plane hard wooden 
surface and tapped volume of packing recorded.
LBD and TBD was calculated using the following formula:
      LBD(Loose Bulk Density)      =        Mass of Powder
                                                                            Volume of packing
                  TBD(Tapped Bulk Density)    =       Mass of Powder
                                                                       Tapped Volume of Packing
2. Compressibility index:
    
            Percentage  compressibility  of  powder  mix  was  determined  by  Carr’s 
compressibility index. Grading of the powders for their flow properties according to arr’s 
index is calculated by following formula.
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                   Carr’s Index %       =       TBD- LBD  x 100     
                                                                     TBD
                      
              Table: 6   Scale of flowability based on Compressibility Index
COMPRESSIBILITY INDEX FLOW CHARACTER
≤ 10 Excellent
11-15 Good
16-20 Fair
21-25 Passable
26-31 Poor
32-37 Very Poor
≥ 38 Very, very Poor
3. Angle of repose
      
               The frictional forces in a loose powder or granules can be measured by the angle of 
repose. This is the maximum angle possible between the surface of a pile of powder or granules 
and the horizontal plane.
                           Tan θ = h/r
Where,
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          θ is the angle of repose,
          h is the height and 
          r is the radius
              The granules were allowed to flow through the funnel fixed to a stand at definite 
height. The angle of repose was then calculated by measuring the height and radius of the heap 
of granules formed.
          
           
Table 7: Flow properties and corresponding angles of repose
FLOW PROPERTY ANGLE OF REPOSE(DEGREES)
Excellent 25-30
Good 31-35
Fair 36-40
Passable 41-45
Poor 46-55
Very Poor 56-65
Very Very Poor >66
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 7
                                                                                                                      Materials and Methods 
Hausner’s Ratio:
        Hausner’s ratio is the ratio of bulk density to the tapped density of powder (or) 
initial volume of the powder mass to the final volume of the powder mass obtained after 
specified number of tapping.
             Table 8: Scale of flowability based on Hausner’s Ratio
HAUSNER’S RATIO FLOW CHARACTER
1-1.1 Excellent
1.12-1.18 Good
1.19-1.25 Fair
1.26-1.34 Passable
1.35-1.45 Poor
1.46-1.59 Very Poor
≥ 1.60 Very, very Poor
COMPRESSION OF FLOATING MATRIX TABLET[41]
                About 60mg of the mixture blend was weighed accurately and fed into the die 
of single punch tablet press and compressed at 1.5N compression force using 6.5mm flat 
punches.
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EVALUATION OF FLOATING MATRIX TABLETS:
1.Weight variation test[41]:
                   20 tablets were selected randomly and weighed. Average weight was 
calculated.  Each tablet  was weighed individually.  Weight of the individual  tablet  was 
compared with the average weight and reported with standard deviation. The tablets meet 
the USP requirements if not more than two tablets are outside the percentage limits and if 
no tablet differs by more than two times the percentage limit.
                     Table 9:      Weight Variation limit of tablets 
        Average weight of tablets                Percentage Deviation  
 130mg or less                      ±  10%
More than 130mg but less than 324mg                      ±   7.5%  
More than 324mg                      ±    5%
 
2.Thickness and diameter:
                   Thickness and diameter were measured during tablet compression using 
digital vernier caliper.
            3. Hardness[42]:
                   Hardness of a tablet can be determined by using Pfizer or Monsanto hardness 
apparatus. The pressure required to break the tablet into fragments is determined. The 
minimum value required for a tablet is 4kg/cm2.
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4. Friability:
   
      Friability is performed to evaluate the ability of the tablet to withstand abrasions. It 
can be determined by using Roche’s friabilator. Ten tablets were weighed and placed in 
the tumbling chamber which was rotated for 100 revolutions. The tablets were deducted 
and again weighed. The loss in weight indicated the friability.
                         Percentage friability  = A-B
                                                                   B
Where A    = initial weight of the tablet
            B    = weight of tablet after 100 revolutions.
5. Assay of Tablet[43]:
•    Preparation of Diluent:
   Buffer:Aceto Nitrile (40:60)
•    Preparation of Buffer:
   Dissolve 250mg of Heptane 1-sulfonic acid of sodium salt in 500ml of water.
                             The concentration of the sample is 10ppm. The measurement of absorption   
                              was found to be 235nm.
6. In-vitro Dissolution[44]:
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        Ezetimibe release from different formulations were determined using a USP XXIII 
paddle apparatus 2 under sink condition. To stimulate in-vivo condition the dissolution 
medium was selected as 900ml HCl buffer with 2% SLS at 37±0.20C. all experiments 
were done in triplicate and average values were taken. The formulations prepared were 
subjected to dissolution tests for 8hrs. Sample were withdrawn at predetermined time 
intervals, filtered through 0.45μm whatman filtr paper and replaced by an equal volume 
of  dissolution  medium.  Absorbance  of  the  diluted  samples  were  determined  by  UV 
spectrophotometer  at  233nm and drug content  was  calculated  using calibration curve 
method.
Dissolution test conditions:
            Apparatus                    : USP XXIII paddle apparatus 2
            RPM                             : 100
            Temperature                 : 37± 0..20 C.
             Medium                       : HCl buffer + 2% SLS
             Duration of test           : 8hrs
             Sampling intervals      : Every one hour
             Sampling volume        : 10ml
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Floating Behaviours[44]:
                Floating behavior studies were carried out in a USP XXIII paddle apparatus 2 at a 
paddle speed of 100 rpm in 900ml HCl buffer(pH 1.2) + 2% SLS at 37±0.20  C. The parameters 
determined were; the time taken by the tablet to go upward and float on the surface ( floating lag 
time), the  time at which the tablet remained buoyant (floating lag time), the time at which the 
tablet remained buoyant (floating duration) and relative matrix integrity (determined on the basis 
of visual inspection).
Related substances:
               The test for related substances was carried out to detect the presence of impurities. The 
sample was made up with a concentration of 10ppm. It was validated with HPLC method against 
system suitability parameters.
DRUG RELEASE KINETICS[45][46]
              To study the release kinetics, data obtained from in-vitro drug release studies were 
plotted in various kinetic models: zero order (Equation 1) as cumulative amount of drug released 
Vs time, first order as log cumulative percentage of the drug remaining Vs time, Higuchi’s model 
(Equation 2) as cumulative percentage of drug released Vs square of time.
                             C=K0t ------------------------------------- (1)
Where,
K0 : is the zero-order rate constant expressed  in units of concentration/time
t  : is the time in hours
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             A graph of concentration Vs time would yield a straight line with a slope equal to K0 and 
intercept the origin of the axis.
               
                            LogC = Log C0- Kt/ 2.303 -------------------------- (2)
Where
  C0 : is the initial concentration of drug,
  K : is the first order constant, and t is the time
                           
                             Q = Kt1/2 --------------------------------------- (3)
Where,
K : is the constant reflecting the design variables of the system
t : is the time in hours. Hence, drug release rate is proportional to the reciprocal of the square 
root of time.
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To  evaluate  the  drug  release  with  changes  in  the  surface  area  and  the  diameter  of  the 
particles/tablets
The data were also plotted using the Hixson- Crowell cube root law 
                             3√Q0 - 3√ Qt = KHC – t -------------------------- (4)
Where,
Qt is the amount of drug released in time t,
Q0 is the initial amount of the drug in the tablet and
KHC is the rate constant for the Hixson-Crowell rate equation, as the cube root of the percentage 
of the drug remaining in the matrix vs time.
Mechanism of Drug Release:
                     To evaluate the mechanism of drug release from Ezetimibe floating matrix tablet, 
data of drug release were plotted in Korsmeyer et al’s equation (equation 5) as log cumulative 
percentage of drug released vs log time, and the exponent n was calculated through the slope of 
the straight line.
                             Mt-M∞ = Ktn --------------------------- (5)
Where,
Mt/M∞ is the fractional solute release,
t is the release time,
K is a kinetic constant characteristic of the drug/polymer system, and
n is an exponent that characterizes the mechanism of release of tracers.
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For  cylindrical  matrix  tablets,  if  the  exponent  n=  0.45,  then  the  drug  release  mechanism is 
Fickian  diffusion,  and  if  0.45≥  n≥  0.89,  then  it  is  non-Fickian  or  anomalous  diffusion,  an 
exponent value of 0.89 is indicative of case-II transport or typical zero-order release.
STABILITY STUDIES[47]
          Stability of a drug in its dosage form at different environmental conditions is important, 
because it determines the expiry date of that formulation. Hence, the stability of the drug in the 
floating matrix  tablet  was studied.  Stability studies were conducted according by storing the 
tablets at 400C± 20C, 70 % RH± 5% for 45 days. The samples were withdrawn at initial, 30th & 
45th  day  and  analyzed  suitably  for  the  physical  characteristics,  drug  content  and  cumulative 
release.
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RESULTS
PRELIMINARY STUDIES
Determination of λmax of Ezetimibe:
Ezetimibe showed absorption maxima at 233nm.
Table 10: Calibration curve of ezetimibe at 233nm:
Concentration(µg/ml) Absorbance
2 0.178
4 0.319
6 0.492
8 0.653
10 0.791
                                      Fig 5: Calibration curve of Ezetimibe
Compatibility Studies by FTIR:
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Fig 6:IR Spectra of Ezetimibe pure drug
Fig 7: IR spectra of HPMC K100
Fig 8: IR spectra of all excipients
2
                                                                                                                      Results and Discussion
Fig 9: IR spectra of Ezetimibe + HPMC K100
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Fig 10: IR spectra of Ezetimibe + All excipients
              Table 11: Characteristic peaks of Ezetimibe and its excipients:
Drug  and 
Excipients
Interpretations
Substituted 
Aromatic Ring
C=N 
stretching
C=O 
stretching
C=F 
stretching
OH C--H  
stretching 
Ezetimibe 830.205 1512.4 1272.31 1404.41 3270.68 1718.26
Ezetimibe  + 
HPMC K 100
830.205 1511.92 1272.31 1404.41 3409.53 1717.78
Ezetimibe + all 
excipients
846.115 1564.47 1165.76 1451.17 3418.21 1726.94
PRECOMPRESSION EVALUATION:
Evaluation of powder blend:
                      Table 12: Results of pre formulation studies of the blend
Formulation Angle  of 
repose 
(θ)
Bulk 
Density 
(g//cm3)
Tapped Density
(g/cm3)
Hausner’s
Ratio
Compressibility/
Carr’s Index
Pure Drug 35022’ 0.254 0.625 2.46 59.36
F1 24013’ 0.292 0.346 1.18 15.6
F2 26021’ 0.284 0.335 1.17 15.2
F3 25019’ 0.293 0.346 1.19 15.3
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F4 22023’ 0.280 0.321 1.14 12.7
F5 26012’ 0.290 0.345 1.18 15.9
F6 22016’ 0.296 0.340 1.14 12.9
POST- COMPRESSION EVALUATION OF FLOATING MATRIX TABLETS
Table 13 : Results of post compression parameters of the tablets
Formulation Weight 
Variation 
(mg)*,
n= 20
Hardness
(kg/cm2)
Thickness
(mm)*,
n=3
Friability
(%)
Assay
(% Drug Content)*
n=3
F1 60±2.8 3.7 2.3 0.034 95.53
F2 59±1.9 3.6 2.1 0.033 98.35
F3 61±2.7 3.4 2.2 0.034 97.64
F4 60±2.2 3.5 2.1 0.034 98.13
F5 58±1.1 3.5 2.3 0.035 98.22
F6 59±3.7 3.6 2.1 0.032 97.34
Evaluation of floating behaviour:
                            Table 14: Results of floating behaviour
Formulation Floating lag time(s) Buoyancy(hrs) Matrix integrity*
F1 53 >12 ++
F2 57 >12 ++
F3 54 >12 ++
F4 30 >12 ++
F5 21 >12 ++
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F6 29 >12 ++
*(-) poor, (+) moderate, (++) good, (+++) excellent
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            Initial   (F5)                                                 After 30s (F5)
                                Fig 12: invitro floating behaivour
Evaluation of In- vitro drug release
Time(hrs) Cumulative Per cent Drug Release
F1 F2 F3 F4 F5 F6
1 26.93 39.34 24.9 17.54 20.85 24.17
2 37.33 46.56 35.2 31.30 33.3 33.64
3 45.79 51.25 47.49 39.12 41.4 38.18
4 50.13 57.42 55.44 47.53 49.56 50.22
5 59.21 64.45 64.45 60.28 59.23 61.93
6 64.89 70.45 72.45 70.87 63.21 72.45
7 71.45 79.67 84.67 80.21 78.23 83.53
8 91.89 85.31 93.12 89.21 96.82 90.12
                          Table 15: In vitro release of Ezetimibe floating tablets 
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                                          Fig 13: In-vitro dissolution studies of F1,F2 and F3
                                     Fig 14: In-vitro dissolution studies of F4, F5 and F6
RELATED SUBSTANCES
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                                           Fig 15: Related substances of SST of Ezetimibe
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                                           Fig 16: Related Substances of Ezetimibe Standard
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                                  Fig 17: Related Substances of Ezetimibe sample
                       Table 16: Results of Related substances
Name Retention time
Standard 19.34
Sample 19.32
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 11
                                                                                                                      Results and Discussion
RELEASE KINETIC ANALYSIS
                                                   Fig 18: plot of Zero order kinetics
Fig 19: plot of First order kinetics
                                             Fig 20: Higuchi’s plot
Fig 21: Korsmeyer - peppas model
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Table 17: Results of kinetic analysis
Formulation Zero order First order Higuchi model Korsmeyer-  peppas 
model
R2 R2 R2 n R2
F1 0.973 0.621 0.936 0.935 0.959
STABILITY STUDIES
Table 18: Results of Stability Studies
Sl. No Parameters Initial 30th day 45th day
1 Physical appearance White White White
2 Assay (% drug content) 98.22 98.25 98.25
3 Floating lag time (s) 31 32 30
4 Floating duration (hrs) More than 8hrs More than 8hrs More than 8hrs
5 Cumulative  %  Drug 
release
96.82 95.12 95.32
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DISCUSSION
PRELIMINARY STUDIES:
Determination of λmax  of Ezetimibe:
       A solution containing (1mg/ml) of Ezetimibe was scanned in the range of 200-400nm. 
Ezetimibe showed absorption maxima at 233nm.
Calibration curve of Ezetimibe:
Calibration curve of Ezetimibe showed good linearity in the range of 10- 50μg/ml with 
Regression coefficient (R2) value of 0.998 as shown in (fig. 5)
Compatibility studies by FTIR:
            Drug polymer interaction was checked by comparing the IR spectra of pure drug with the 
IR spectra of physical mixture of drug and excipients used.
IR spectra matching approach was used for detection of any possible chemical interaction 
between drug and polymer. All the characteristic peaks of Ezetimibe were also found in the IR 
spectra of physical mixtures.(Table 11)
          Frequencies of functional groups of pure drug remained intact in physical mixtures 
containing  different  polymers.  Hence  there  was  no  major  interaction  during  the  drug  and 
excipients used in this study.
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PRECOMPRESSION EVALUATION:
Evaluation of the powder blend:
               All materials were properly mixed as per compostion shown in table(12). For each 
designed  formulation,  blend  of  drug  and  excipient  were  prepared  and  subjected  to  pre 
compression parameters like angle of repose, bulk density, tapped density, compressibility index 
and hausner’s ratio like the obtained results were shown in Table- 12
                  As a general guide,  powders with angle of repose greater than 400C have 
unsatisfactory flow properties, whereas minimum angles close to 250 correspond to very good 
flow properties. The angle of  repose range between 22016’ to 26021’, which indicates good flow 
properties of powders.
                 The bulk density and tapped density for all formulation were found to be in the range 
of 0.280 to 0.296 gm/cm3 and 0.321 to 0.346 g/ cm3 respectively, which indicates good packing 
character.
The powder has good flowability, when the Hausner’s ratio is lower than 1.2 and when the value 
exceeds 1.2, it indicates poor flow. Compressibility is indirectly related to the relative flow rate, 
cohesiveness and particle size of a powder. A compressibility material will be less flowable, and 
the powders with compressibility values greater than 20-21 % have found to exhibit poor flow 
properties. The hausner’s ratio and percentage compressibility index was found to be in the range 
1.14 to 1.18 and 12.7% to 15.9% respectively, which supports the fact that these formulations 
have good flow and compaction properties.
All formulations exhibited good flow property and compressibility which is very essential for 
direct compression and hence tablet was prepared by using direct compression technology.
COMPRESSION OF TABLETS
             The floating matrix tablets were prepared by direct compression technique. The target 
weight of the prepared tablet  was 60mg. the desired hardness in between 3-5kg/cm2.  All the 
tablets were found to be uniform in size and shape and no processing problems were encountered 
during compression process.
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POST-COMPRESSION EVALUATION OF FLOATING MATRIX TABLETS:
Evaluation of physical parameter:
                The compressed tablets were evaluated for the weight variation, hardness, thickness, 
friability and content uniformity as per Indian Pharmacopoeia and the results were shown in 
table (13)
All the compressed tablets passed the weight variation test. The mean thickness of the 
prepared tablets was found to be in between 2.1 to 2.3mm. The mean hardness of the tablets 
ranged from 3.4 to 3.7 kg/ cm2. Percentage friability ranged from 0.032% to 0.035 %. The drug 
content in all the prepared tablets complied with the Indian Pharmacopoeia requirements, which 
was found to lie within the range of 95.53% to 98.35%.
All values of the physical parameter were found to be within the Pharmacopoeial limits.
Evaluation of floating behaviours:
                 The parameters determined were: 
Floating lag time – the time taken by the tablet to reach the surface and float.
Floating  duration:  the  time  at  which  the  tablet  remained  buoyant,  matrix 
integrity( determined on the basis of visual inspection); and the results were shown in (Table)
Sodium bicarbonate  was  used as  the  effervescent  base.  Upon contact  with  the acidic 
medium,  the  fluid  permeated  into  the  tablet,  causing  neutralization  reaction  to  occur,  which 
generates Carbon dioxide (CO2).  The swelling polymer traps the CO2 so generated and thus 
provides continued buoyancy.
The floating lag time was found to be in the range of 29 to 53 seconds. Increase in the 
effervescent agent led to decrease in the floating lag time (table 14). 
Formulations containing higher concentrations of polymer showed structural integrity and 
and buoyancy time of more than 12 hours.
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Evaluation of in-vitro drug release:
          Ezetimibe was released from different formulations as determined in 900ml HCl + 2% 
SLS medium at 37± 0.20C.
It  was  observed  that  as  the  concentration  of  polymer  increases,  the  drug  release  is 
decreased. HPMC K4, HPMC K 15, HPMC K 100 being highly swellable polymers were able to 
swell to an considerable extent and thus concentration increased and thus forms a thick viscous 
layer around the matrix tablet.
Related Substances:
The formulation was evaluated for impurities by HPLC method. Since the retention time 
of the standard and sample is same i.e 19.32, the formulation was analysed to be pure.
DRUG RELEASE KINETICS:
               The in-vitro drug dissolution data was analyzed for establishing kinetics of drug 
release. Model fitting was done (Zero- order,  first-order, Higuchi, Korsmeyer-peppas model). 
Interpretations of data  were based on regression coefficient.  The kinetic  analysis  of the best 
formulation was shown.(Table 17).
The R2 values obtained from zero order plots was found to be higher in comparison to 
first order plot which suggest that the drug release rate from the prepared tablets were in constant 
and controlled manner. The data suggest that most of the formulation fit into Higuchi’s equation 
for the release of drug from the homogeneous polymeric matrix that depends mostly on diffusion 
characteristics.
Further  to  identify  the  release  mechanism  of  ezetimibe  from  matrix  tablets,  the 
dissolution data were fitted to korsmeyer-peppas diffusion model. The ‘n’ values for HPMC K4, 
HPMC K100, HPMC 15 ranged from (0.45<n<0.89) which indicates that the release mechanism 
was non-fickian or diffusion.
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STABILITY STUDIES:
           Accelerated stability studies carried out according ICH guidelines. Optimized formulation 
(F5) were sealed in aluminium packaging coated inside with polyethylene, and kept in stability 
chamber at 400C ± 2⁰C and 75% ± 5% RH for 45 days. At the end of the period, sample were 
analysed for drug content, floating characteristics and in-vitro drug release as shown (Table 18). 
           Stability study of optimized formulation revealed no significant change in physical 
appearance, drug content, floating lag time, floating duration as well as  in- vitro drug release. 
And hence the optimized formulation were found to be stable at 40⁰C ± 2⁰C and 75%± 5% RH 
for 45 days.
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                                                         SUMMARY
        
               The present study was aimed at preparing floating  matrix tablets containing Ezetimibe 
based on gas formation technique in order to increase the gastric retention time for enhancing 
controlled release of the drug for a longer time. Ezetimibe shows pH dependent solubility and 
stability, it is more soluble and stable in acidic than alkaline pH. Hence, it will be beneficial to 
increase its gastric residence time.
FORMULATION DESIGN:
            In this study, floating matrix tablets of Ezetimibe were prepared based on effervescent 
technique using HPMC K4, HPMC K15, HPMC K100 as (matrix forming swellable polymers), 
sodium bicarbonate (effervescent  compound) and PG Starch.  A total  of 6 formulations  were 
designed by varying the amounts of polymer and sodium bicarbonate at 2 levels (low and high) 
using cross over design.
PRE- COMPRESSION STUDIES:
             The prepared powder blends  of  all  the 6  formulations were evaluated for  pre-
compression parameters like angle of repose, bulk  density, tapped density, compressibility index 
and Hausner’s ratio. The results obtained from these studies showed that the prepared blends 
were having satisfactory fluidity and compressibility; hence tablets can be prepared by direct 
compression method.
            IR spectra matching approach was used for detection of any possible chemical interaction 
between drug and polymers. This study revealed that there was no major interaction between the 
drug and excipients used.
COMPRESSION OF TABLETS:
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                The floating matrix tablets were prepared by direct compression technique using 
single punch tablet press at a compression force (1.5 N) in a concave punches (6.5mm). the target 
weight of the prepared tablet was 60mg. The desired hardness is between 3-5 kg/cm2. All the 
tablets were found to be uniform in size and shape and no processing problems were encountered 
during compression process.
POST- COMPRESSION STUDIES:
               The compressed tablets were evaluated for their weight variation, hardness, thickness, 
friability and content uniformity as per Indian pharmacopoeia and the results were found to be 
within the prescribed limits.
                    Floating behaviour  were carried out in a USP XXIII paddle apparatus 2 at a paddle 
speed of 100rpm  in 900ml HCl and 2% SLS at 37±0.2⁰C. The parameters determined were 
Floating lag time, Floating duration  and Relative matrix integrity). Floating lag time for all 
formulation were found to be less than 5 minutes.  Formulations containing high concentration of 
polymer  showed  structural  integrity  and  buoyancy  time  of  more  than  12  hrs,  while  others 
formulations, while others formulations showed rapid disintegration on contact with dissolution 
media.
       Ezetimibe release from different formulations was determined using a USP XXIII paddle 
apparatus 2 at paddle speed of 100rpm in 900ml HCl buffer (pH 1.2) at 37±0.2⁰C under sink 
condition for 10hrs. In this study, it was observed that as the concentration of polymer increase, 
the drug release decreases.
         The in vitro drug dissolution data obtained for the best formulation were plotted in various 
kinetic models for establishing kinetics of drug release. Zero order plot suggests that the drug 
release rate from the prepared tablets were in constant and controlled manner.  The data also 
suggest that the formulation fit into Higuchi’s equation  for the release of the drug from the 
homogeneous  polymeric  matrix  that  depends  mostly  on  diffusion  characteristics.  From  the 
korsmeyers- peppas diffusion model the release mechanism of Ezetimibe  from matrix was found 
to be Case- II Transport or typical zero order release.
2
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The test for Related substances was carried out for the optimized formulation and it was found 
that the formulation was free from impurities.
Accelerated stability studies were carried out for the optimized formulation (F5) in a stability 
chamber at 40⁰C ± 2⁰C and 75% ± 5% RH for 45 days . The study showed no significant 
change in physical appearance, drug content, floating lag time, floating duration  as well as in-
vitro drug release, hence the formulation was found to be stable.
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Conclusion 
CONCLUSION
               In the present study, floating matrix tablets have been formulated with Ezetimibe with 
the help of polymers such as HPMC K4, HPM C K 100 and HPMC K 15. Effervescent technique 
was used to keep the tablets floating over the simulated gastric fluid (pH 1.2) for 24 hrs. All the 
formulations showed floating lag time less than 1 minute. Sodium bicarbonate was found to be 
good effervescent base. The drug release mechanisms for this formulation was found to be of 
zero order and diffusion. The formulation F5 was selected as optimized formulations because it 
gave  the  best  results  in  terms  of  the  required  in-vitro buoyancy  as  well  as  drug  release  in 
sustained manner and was also found to be stable under stability conditions.
Thus,  the  results  of  the  current  studies  indicates,  a  promising  potential  of  ezetimibe 
floating matrix tablet as an alternative to conventional dosage form. Further, clinical studies are 
needed to assess the utility of this system for patient suffering from hypercholesterolemia. 
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